Skip to main content

Table 1 Main clinical features according to Nestin status in patients with advance HCC (n = 220)

From: Nestin overexpression in hepatocellular carcinoma associates with epithelial-mesenchymal transition and chemoresistance

Clinical and pathological indexes   Nestin expression  
Total Low High P
n n (%) n (%)  
Age (years) ≤ 60 118 52(44.1) 66(55.9) 0.119
  > 60 102 54(52.9) 48(47.1)  
Gender Male 109 49(45.0) 60(55.0) 0.208
  Female 111 57(51.4) 54(48.6)  
HBsAg Negative 120 59(49.2) 61(50.8) 0.427
  Positive 100 47(47.0) 53(53.0)  
Albumin ≤ 35 g/L 124 57(46.0) 67(54.0) 0.498
  > 35 g/L 96 49(51.0) 47(49.0)  
Liver cirrhosis Absent 73 40(54.8) 33(45.2) 0.107
  Present 147 66(44.9) 81(55.1)  
Child-Pugh stage A 120 57(47.5) 63(52.5) 0.466
  B 100 49(49.0) 51(51.0)  
AFP (ng/ml) ≤ 20 77 35(45.5) 42(54.5) 0.326
  > 20 143 71(49.7) 72(50.3)  
Edmondson-Steiner grade I-II 96 52(54.2) 44(45.8) 0.077
  III-IV 124 54(43.5) 70(56.5)  
Macroscopic vascular invasion Absent 104 61(58.7) 43(41.3) 0.002 *
  Present 116 45(38.8) 71(61.2)  
BCLC stage B 86 52(60.5) 34(39.5) 0.003 *
  C 134 54(40.3) 80(59.7)  
Disease status Confined to the liver 100 57(57.0) 43(43.0) 0.012 *
  Metastatic disease 120 49(40.8) 71(59.2)  
  1. Abbreviations: BCLC stage Barcelona Clinic Liver Cancer
  2. *significant difference is shown in bold